A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

B, Kuenen; PO, Witteveen; R, Ruijter; G, Giaccone; A, Dontabhaktuni; F, Fox; T, Katz; H, Youssoufian; J, Zhu; EK, Rowinsky; EE, Voest

doi:10.1158/1078-0432.ccr-09-2425

Public

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Shared by NobleBlocks on Mar 2, 2010 • 12:00 AM UTC

Authors:

Kuenen B

Witteveen PO

Ruijter R

Abstract

<h4>Purpose</h4>This study aimed to determine a maximum tolerated dose (MTD) and recommended dose for disease-directed studies of necitumumab (IMC-11F8), a fully human IgG(1) monoclonal antibody directed at the epidermal growth factor receptor, and to characterize the safety profile, pharmacokinetic...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!